| Autor: |
Basma Alahideb, Dalia A. Obeid, Suliman Aljumaah, Sara Altamimi, Reem S. Almaghrabi, Mohamed Asiri, Maha Al-Abdulkarim, Shuruq Almutairi, Maysoon Mutabagani, Madain Alsanea, Fatimah S. Alhamlan, Sahar Althawadi, Jalwa Alkahtani, Khaled Alnafee, Salem Alghamdi, Ahmed A. Al-Qahtani, Feda Alsuwairi |
| Rok vydání: |
2021 |
| Předmět: |
|
| DOI: |
10.21203/rs.3.rs-779549/v1 |
| Popis: |
Despite the effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines against SARS-CoV-2, the delta (B.1.617.2) variant of concern (VOC) has spread globally, and breakthrough infections have been reported. We identified the circulating variants and effectiveness of those vaccines between April and June 2021 at a tertiary-care hospital in Saudi Arabia. Among 320 patients with confirmed COVID-19 (mean age, 39 years; 53.6% male), 70.6% received a one-dose vaccination; 15.1% received two-dose vaccinations; 14. 3% were unvaccinated; 64.9% received Oxford-AstraZeneca; and 32.5% received Pfizer-BioNTech. Most breakthrough cases involving VOCs (71%) occurred among patients who received a one-dose Oxford-AstraZeneca vaccination, and most patients with breakthrough disease were infected with the delta variant. Among all VOCs and non-VOCS, the delta variant was most frequently detected and was associated with young age (20–49 years), males, symptoms, and low cycle threshold value. These findings indicate an increased rate of transmission for the delta variant in this cohort. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
